Can moxifloxacin be co‑administered with bisoprolol safely?

Can Moxifloxacin and Bisoprolol Be Taken Together?

Moxifloxacin and bisoprolol can be co-administered, but this combination requires careful cardiac monitoring due to additive QT prolongation risk, particularly in patients with pre-existing cardiac conditions, bradycardia, or electrolyte disturbances.

Key Safety Concern: QT Prolongation

The primary concern with this combination is additive QT interval prolongation. Moxifloxacin is well-documented to prolong the QTc interval 1, while bisoprolol—though not typically classified as a QT-prolonging agent—can cause clinically relevant bradycardia 2, 3, which itself is a risk factor for QT prolongation and torsades de pointes.

Guideline-Based Contraindications for Moxifloxacin

According to British Thoracic Society guidelines, moxifloxacin should not be used in patients with 1:

• Congenital or acquired QT prolongation
• Clinically relevant bradycardia (directly relevant to bisoprolol use)
• Clinically relevant heart failure with reduced ejection fraction
• History of symptomatic arrhythmias
• Uncorrected hypokalaemia
• Concurrent use with other drugs that prolong the QT interval

Beta-Blocker Interaction Specificity

The guidelines specifically mention that beta-blockers increase the risk of ventricular arrhythmias with moxifloxacin, particularly sotalol 1. While sotalol (a Class III antiarrhythmic with inherent QT-prolonging properties) is explicitly called out, the concern extends to bradycardia induced by any beta-blocker, including bisoprolol.

Clinical Decision Algorithm

When Co-Administration May Be Acceptable:

1. Patient has no cardiac risk factors:

   • No history of arrhythmias, heart failure, or structural heart disease
   • Normal baseline heart rate (>60 bpm)
   • Normal electrolytes (particularly potassium and magnesium)
   • No other QT-prolonging medications 4

2. Mandatory monitoring requirements 1:

   • Baseline ECG before starting moxifloxacin
   • Repeat ECG at 2 weeks
   • ECG after addition of any new QT-prolonging medication
   • Monitor serum potassium and magnesium throughout treatment
   • Clinical assessment for syncope, palpitations, or presyncope

When to Avoid This Combination:

Do not co-administer if the patient has 1:

• Baseline bradycardia (<60 bpm or symptomatic)
• Heart failure with reduced ejection fraction
• History of QT prolongation or arrhythmias
• Concurrent use of other QT-prolonging drugs (see list below)
• Uncorrected electrolyte abnormalities
• Advanced age (>80 years) with multiple cardiac risk factors

Common QT-Prolonging Medications to Avoid

If the patient is on bisoprolol and moxifloxacin, avoid adding 4:

• Antiarrhythmics: amiodarone, sotalol, quinidine, procainamide
• Antipsychotics: haloperidol, droperidol, phenothiazines
• Antiemetics: ondansetron, domperidone, metoclopramide
• Macrolides: erythromycin (IV), clarithromycin, azithromycin
• Antimalarials: chloroquine, hydroxychloroquine
• Antidepressants: tricyclics

Additional Drug Interaction Considerations

No Pharmacokinetic Interaction Expected

Importantly, moxifloxacin does not interact pharmacokinetically with bisoprolol. Moxifloxacin is not metabolized by CYP450 enzymes 5, 6 and does not affect beta-blocker metabolism. The FDA label confirms no significant interactions with atenolol (another beta-blocker) 5, suggesting bisoprolol would behave similarly.

Other Moxifloxacin Interactions to Manage

If prescribing both drugs, ensure 5:

• Separate moxifloxacin from antacids, iron, or multivitamins by 4 hours before or 8 hours after
• Monitor blood glucose if patient is diabetic (moxifloxacin can cause hypoglycemia)
• Monitor INR if patient is on warfarin

Practical Clinical Approach

If moxifloxacin is clinically necessary in a patient on bisoprolol:

1. Assess cardiac risk (history, baseline HR, ECG, electrolytes)
2. If low risk: Proceed with baseline ECG, correct electrolytes, and schedule 2-week follow-up ECG
3. If moderate-to-high risk: Consider alternative antibiotics (levofloxacin has lower QT risk, or use non-fluoroquinolone options like doxycycline, amoxicillin-clavulanate) 7, 8
4. Monitor for symptoms: Instruct patient to report dizziness, syncope, or palpitations immediately
5. Consider temporary bisoprolol dose reduction if bradycardia develops (HR <50 bpm)

Common Pitfalls to Avoid

• Assuming all beta-blockers are equivalent: Sotalol is explicitly contraindicated; bisoprolol is safer but still requires caution due to bradycardia risk
• Neglecting electrolyte monitoring: Hypokalaemia dramatically increases torsades risk with moxifloxacin 1
• Failing to obtain baseline ECG: Without baseline QTc, you cannot assess drug-induced changes
• Overlooking other QT-prolonging drugs: Polypharmacy with multiple QT-prolonging agents exponentially increases risk 9
• Ignoring age and renal function: Elderly patients (≥80 years) and those with renal impairment have higher moxifloxacin exposure and greater arrhythmia risk 10, 11